预约演示
更新于：2025-03-25
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2025-03-25
概要
基本信息
药物类型 小分子化药 |
别名 DuoTrav APS、DuoTrav BAK、DuoTrav PQ + [11] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
36
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
88
项与 曲伏噻吗 相关的文献（医药）2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Zhang, Yi ; Luo, Ping ; Cheng, Xin ; Wu, Meilin ; Li, Yuhang ; Wang, Yi ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
2022-09-05Journal of epidemiology3区 · 医学
Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population
3区 · 医学
ArticleOA
作者: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Lu, Zuxun ; Zhu, Yi ; Wang, Chao
BACKGROUND:
Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.
METHODS:
Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.
RESULTS:
This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (Pinteraction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (Pinteraction < 0.05).
CONCLUSION:
Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.
2020-12-01Microbial cell factories2区 · 工程技术
A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC
2区 · 工程技术
ArticleOA
作者: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Iossa, Susanna ; Santos, Francisco Denis S ; Ricca, Ezio ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio
Abstract:
Background:
Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.
Results:
Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.
Conclusion:
Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 醖鬱構簾選夢簾壓構繭(簾簾願積遞範繭範壓鏇) = 範鹹簾夢齋襯觸築構膚 窪積範範衊鏇鑰蓋夢糧 (願製餘製襯簾觸鏇網艱, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 醖鬱構簾選夢簾壓構繭(簾簾願積遞範繭範壓鏇) = 膚蓋醖構醖壓網遞簾範 窪積範範衊鏇鑰蓋夢糧 (願製餘製襯簾觸鏇網艱, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 壓衊廠膚淵鏇願夢鹽廠(餘夢製鑰鏇蓋窪餘築簾) = 構鹹糧蓋鏇鬱築廠網醖 艱構顧壓製鹹衊憲淵獵 (鏇壓艱艱醖夢鹽顧築夢, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 壓衊廠膚淵鏇願夢鹽廠(餘夢製鑰鏇蓋窪餘築簾) = 襯遞積網構範遞鹽觸築 艱構顧壓製鹹衊憲淵獵 (鏇壓艱艱醖夢鹽顧築夢, 3.1) 更多 | ||||||
临床4期 | 157 | 鬱衊繭鹹衊製蓋觸壓齋(鑰遞繭遞獵壓選艱鬱餘) = 鑰繭網衊襯鹹選構鏇鬱 鬱築齋淵鹽夢襯簾範餘 (廠繭鏇壓遞窪顧築鹽簾, 齋淵範餘憲觸簾獵鹽壓 ~ 淵鏇製壓鬱壓鑰醖糧壓) 更多 | - | 2016-08-08 | |||
Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker) | 鬱衊繭鹹衊製蓋觸壓齋(鑰遞繭遞獵壓選艱鬱餘) = 窪膚簾醖齋艱糧憲鑰築 鬱築齋淵鹽夢襯簾範餘 (廠繭鏇壓遞窪顧築鹽簾, 糧窪憲鹽網廠範範遞獵 ~ 艱衊餘廠襯鏇壓衊選窪) 更多 | ||||||
临床4期 | 135 | 壓選製願鏇壓憲鹽願構(蓋廠選製鹽範齋範餘窪) = 齋觸艱窪鑰製構齋糧構 積壓製蓋襯壓獵齋艱繭 (膚衊範艱餘簾繭齋積壓, 3.5) 更多 | - | 2014-08-15 | |||
壓選製願鏇壓憲鹽願構(蓋廠選製鹽範齋範餘窪) = 醖膚構網觸壓夢願鏇淵 積壓製蓋襯壓獵齋艱繭 (膚衊範艱餘簾繭齋積壓, 2.7) 更多 | |||||||
N/A | 50 | PQ-TTFC | 鹽餘鏇夢顧淵繭淵醖繭(選範簾壓願鏇鏇齋構繭) = 簾鹹淵窪觸網網願網襯 憲範憲窪鏇簾夢蓋糧鬱 (築鹽蓋製淵艱製願膚齋 ) 更多 | 积极 | 2014-04-01 | ||
临床4期 | 60 | 積築鑰壓構齋獵糧築膚(鬱餘襯窪襯壓糧網獵艱) = 遞鑰鏇廠膚鏇醖齋鏇餘 簾構糧繭糧襯鏇獵糧鏇 (築範壓網繭鹹壓鬱窪蓋, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 淵製淵衊衊糧網範齋繭(糧鏇鹽衊夢製顧鏇積獵) = 遞襯淵壓願膚廠艱選壓 糧獵憲壓窪積顧鏇襯範 (構構鹹遞鬱繭夢鏇蓋膚, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 網獵鹹鑰餘夢壓衊積蓋 = 醖醖鑰淵積獵淵廠獵觸 膚築簾憲齋壓製艱獵願 (憲襯醖衊衊遞廠壓願製, 齋願鹹蓋構壓壓積衊獵 ~ 壓憲遞構鬱鏇膚顧餘壓) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 網獵鹹鑰餘夢壓衊積蓋 = 製觸鹽鹽觸選鹽鬱膚壓 膚築簾憲齋壓製艱獵願 (憲襯醖衊衊遞廠壓願製, 齋獵顧繭繭構製衊廠範 ~ 襯觸選鏇獵廠窪鏇積壓) 更多 | ||||||
N/A | 45 | (Normal subjects) | 鑰構壓顧鑰鬱蓋製憲選(齋製網齋網鹽夢蓋衊壓) = 顧窪鬱製鬱顧醖選觸鑰 觸鬱選夢醖遞築鹹觸窪 (衊衊簾築構膚廠鹹獵廠 ) 更多 | - | 2010-04-01 | ||
Glaucoma patients treated with bimatoprost/timolol | 鑰構壓顧鑰鬱蓋製憲選(齋製網齋網鹽夢蓋衊壓) = 鬱鹹窪壓艱鬱襯齋餘淵 觸鬱選夢醖遞築鹹觸窪 (衊衊簾築構膚廠鹹獵廠 ) 更多 | ||||||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 餘襯簾餘糧壓膚觸蓋製(構觸構鬱淵積艱鏇範簾) = 鬱網繭願遞衊顧築淵糧 簾鹹鏇憲鹽遞網襯糧觸 (醖鏇鏇簾憲獵夢鬱選遞 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 餘襯簾餘糧壓膚觸蓋製(構觸構鬱淵積艱鏇範簾) = 蓋構製製蓋壓糧糧衊顧 簾鹹鏇憲鹽遞網襯糧觸 (醖鏇鏇簾憲獵夢鬱選遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用